Analytical treatment interruption as a tool in the evaluation of immune-mediated interventions for long-term antiretroviral-free control of HIV-1 among people with HIV
Por:
dos Santos, AGP, Abunimeh, M, Mothe, B, Routy, JP, Lalezari, JP, Sinclair, GI, Sokhela, SM, Diaz, RS, Schwarze, S, Berry, J, Lewin, SR, Dubé, K, Krishnan, P, Topp, A, Gill, S and Cohen, D
Publicada:
1 ene 2026
Ahead of Print:
1 ene 2025
Resumen:
Background: Immune-mediated interventions have the potential to induce long-term antiretroviral treatment (ART)-free viral suppression in people with HIV. However, in the absence of biomarkers of viral control, studies looking at immune interventions require a planned long-term analytical treatment interruption (ATI) that may bring risks to participants and challenges for data interpretation. Herein, we describe an ongoing, global, proof-of-concept, randomized, placebo-controlled, phase 2 clinical trial with a planned ATI and illustrate how those risks have been mitigated to safely evaluate the long-term durability of ART-free viral control. Methods: The trial evaluates an immunologic combination of low-dose budigalimab and trosunilimab administered during ATI. Adults aged 18-70 with confirmed HIV-1 on stable ART with viremia below the limit of detection and CD4+ counts >500 cells/mL willing to undergo ATI are randomized to receive budigalimab, trosunilimab, both (at 2 different trosunilimab doses), or neither. The primary efficacy endpoint is the proportion of participants achieving viral control (HIV-1 RNA <1000 copies/mL) without restarting ART at week 24. The planned ATI duration (<= 112 weeks) evaluates the durability of off-ART viral control, long-term safety, and biomarkers. Key ATI elements align with published consensus recommendations [1] while incorporating feedback from members of the global HIV community. Conclusions: By sharing this study design, we hope to inform on the lessons learned from operationalizing a global study evaluating durable ART-free viral control, including the critical role of engaging members of the HIV community during clinical trial design to ensure the success of an ATI-inclusive study.
Filiaciones:
dos Santos, AGP:
AbbVie Inc, N Chicago, IL 60064 USA
Abunimeh, M:
AbbVie Inc, N Chicago, IL 60064 USA
:
Hosp Germans Trias & Pujol Badalona, Dept Infect Dis, Barcelona, Spain
Hosp Germans Trias & Pujol Badalona, IrsiCaixa, Barcelona, Spain
Inst Salud Carlos III, CIBER Enfermedades Infecciosas CIBERInfec, Madrid, Spain
Univ Vic, Cent Univ Catalonia, Vic, Spain
Routy, JP:
McGill Univ, Hlth Ctr, Montreal, PQ, Canada
Lalezari, JP:
Quest Clin Res, San Francisco, CA USA
Sinclair, GI:
Prism Hlth North Texas, Dallas, TX USA
Sokhela, SM:
Univ Witwatersrand, Ezintsha, Johannesburg, South Africa
Diaz, RS:
Univ Fed Sao Paulo, Sao Paulo, Brazil
Schwarze, S:
Projekt Informat eV, Berlin, Germany
Berry, J:
Reun Project, Calabasas, CA USA
Lewin, SR:
Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Infect Dis, Melbourne, Vic, Australia
Royal Melbourne Hosp, Peter Doherty Inst Infect & Immun, Victorian Infect Dis Serv, Melbourne, Vic, Australia
Alfred Hosp, Dept Infect Dis, Melbourne, Vic, Australia
Monash Univ, Melbourne, Vic, Australia
Dubé, K:
Univ Calif San Diego, San Diego, CA USA
Krishnan, P:
AbbVie Inc, N Chicago, IL 60064 USA
Topp, A:
AbbVie Inc, N Chicago, IL 60064 USA
Gill, S:
AbbVie Inc, N Chicago, IL 60064 USA
Cohen, D:
AbbVie Inc, N Chicago, IL 60064 USA
hybrid
|